O’Brien Medical Awarded Grant for ETF Feature Enhancement

The company is pleased to announce recent seed grant approval from the Maine Technology Institute (MTI). The award will be used to develop a proof-of-concept prototype designed to extend the feature set of the company’s core product, the ETF.  Much of the work will be done in collaboration with the University of Maine’s Department of Chemical and Biomedical Engineering. Funding will also cover patent filing on the novel prototype.”We’re excited to work with MTI and UMaine to push the boundaries of clinical care diagnostics.” said company CEO, Todd O’Brien.  ” The extended capabilities we’re developing for the ETF will provide a unique approach for assessing neuropathy in a point-of-care setting”.


ETFMx and ETF128